Theratechnologies picks Huss as president, CEO

Theratechnologies (TSX:TH) has named John-Michel Huss as president and CEO, succeeding Yves Rosconi, who previously informed the board of his decision to retire by the end of the year.

Mr. Huss will assume the two posts in coming months. He was most recently chief of staff, office of the CEO, of Sanofi-Aventis in Paris and has over 20 years experience in the pharmaceutical industry in various international positions.

“The company has done an outstanding job of developing an exciting new compound, tesamorelin, and navigating it through the final regulatory stages of the drug development process,” Mr. Huss said in a statement. “I very much look forward to joining Theratechnologies at this stage of development in order to grow it into a significant biopharmaceutical company.”